What is Gradient Denervation Technologies?
Based in Paris, Gradient Denervation Technologies is a specialized medical device enterprise dedicated to the development of a novel, minimally invasive system for treating pulmonary hypertension. The company's core technology utilizes therapeutic ultrasound energy to perform targeted nerve ablation around the pulmonary artery. This approach is designed to provide a viable alternative for patients who currently face limited therapeutic options. By leveraging intellectual property originating from Stanford University, the firm occupies a unique niche at the intersection of cardiovascular medicine and advanced engineering. Their primary market focus encompasses healthcare providers and clinical institutions seeking to improve outcomes for patients with complex heart failure conditions.
How much funding has Gradient Denervation Technologies raised?
Gradient Denervation Technologies has raised a total of $15M across 1 funding round:
Series A
$15M
Series A (2023): $15M with participation from Sofinnova Partners, Thuja Capital, and Asabys Partners
Key Investors in Gradient Denervation Technologies
Sofinnova Partners
A prominent European venture capital firm specializing in life sciences, providing hands-on support from seed to later-stage investments.
Thuja Capital
An early-stage venture capital firm focused on partnering with visionary CEOs to drive transformative impact in the life sciences sector.
Asabys Partners
A Barcelona-based investment firm dedicated to fostering breakthrough innovation in healthcare and life sciences through disruptive scientific advancements.
What's next for Gradient Denervation Technologies?
Looking ahead, the company is poised to leverage its recent capital influx to scale its operational capabilities and advance its clinical trial roadmap. The strategic focus will likely center on refining the Gradient Denervation System to meet rigorous regulatory standards while expanding its footprint within the European and global medical device markets. As the firm moves forward, the integration of its ultrasound technology into standard clinical workflows will be a critical milestone. With the support of its seasoned investor syndicate, Gradient Denervation Technologies is strategically aligned to transform the treatment landscape for pulmonary hypertension, potentially setting a new benchmark for minimally invasive cardiovascular care.
See full Gradient Denervation Technologies company page
